Astrazeneca (AZN) Invested Capital (2009 - 2026)

Astrazeneca has reported Invested Capital for 18 years, with the latest figure at $50.4 billion in Q2 2026.

• On a quarterly basis, Invested Capital rose 12.41% year-over-year to $50.4 billion in Q2 2026; TTM through Jun 2026 was $50.4 billion, a 12.41% increase from a year earlier, with the FY2025 full-year figure at $48.7 billion, up 19.34% from the prior year.
• Invested Capital was $50.4 billion for Q2 2026 at Astrazeneca, up from $29.4 billion in the prior quarter.
• The five-year high for Invested Capital was $50.4 billion in Q2 2026, with the low at $24.1 billion in Q1 2024.
• Average Invested Capital over 5 years is $35.8 billion, with a median of $36.4 billion recorded in 2022.
• The largest YoY upside for Invested Capital was 171.75% in 2022 against a maximum downside of 20.68% in 2022.
• Over 5 years, Invested Capital stood at $36.9 billion in 2022, then climbed by 5.66% to $39.0 billion in 2023, then advanced by 4.75% to $40.8 billion in 2024, then rose by 19.34% to $48.7 billion in 2025, then gained by 3.42% to $50.4 billion in 2026.
• The last three Invested Capital figures came in at $50.4 billion (Q2 2026), $29.4 billion (Q1 2026), and $48.7 billion (Q4 2025), per Business Quant data.